NCT05488678View on ClinicalTrials.gov

Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

November 23, 2023

Study Completion Date

November 23, 2023

Conditions
Pharmacokinetics
Interventions
DRUG

VNRX-7145

single oral dose

DRUG

Ceftibuten

single oral dose

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33147

Advanced Pharma, Miami

55114

Nucleus Network, Saint Paul

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Venatorx Pharmaceuticals, Inc.

INDUSTRY